Hewlett-Packard Company (NYSE:HPQ) had its price objective hosited by Mizuho from $30.00 to $35.00 in a report released on Thursday. Mizuho currently has a neutral rating on the stock.Hewlett-Packard Company (NYSE:HPQ) net profit margin is 4.90% and weekly performance is 4.39%. On last trading day company shares ended up $35.16. Analysts mean target price for the company is $35.24. Hewlett-Packard Company (NYSE:HPQ) distance from 50-day simple moving average is 7.66%.
As a result of stronger than expected demand for business PCs, Intel Corporation (NASDAQ:INTC) now expects second-quarter revenue to be $13.7 billion, plus or minus $300 million, as compared to the previous range of $13.0 billion, plus or minus $500 million. Intel Corporation (NASDAQ:INTC) shares advanced 6.83% in last trading session and ended the day on $29.87. INTC Gross Margin is 60.60% and its return on assets is 10.50%. Intel Corporation (NASDAQ:INTC) quarterly performance is 22.97%.
In a research note released Thursday, D.A. Davidson analyst Thomas Diffely increased his price target on Applied Materials (NASDAQ: AMAT) from $21 to $25 and reiterated a Buy rating. Applied Materials, Inc. (NASDAQ:AMAT) shares moved up 2.85% in last trading session and was closed at $22.37, while trading in range of $21.85-$22.42. Applied Materials, Inc. (NASDAQ:AMAT) year to date performance is 27.83%.
Globalstar, Inc. (NYSEMKT:GSAT) is hoping to open up the satellite telephony market to a wider audience with the introduction of its first pre-paid service. Pricing pre-paid satellite calls at a!0.48 (US$0.65) per minute makes using satellites affordable for anyone frustrated by inadequate mobile network coverage, according to Globalstar. Globalstar, Inc. (NYSEMKT:GSAT) ended the last trading day at $4.21. Company weekly volatility is calculated as 6.40% and price to cash ratio as 142.80. Globalstar, Inc. (NYSEMKT:GSAT) showed a positive weekly performance of 11.08%.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm’s lead selective inhibitor of nuclear export (SINE), Selinexor (KPT-330), in combination with “low-dose” (20 mg twice weekly) dexamethasone. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is 87.12%. On last trading day company shares ended up $47.12. Analysts mean target price for the company is $48.25. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average is 68.37%.